Orthomyxoviridae (e.g., Influenza Virus, Fowl Plague Virus, Etc.) Patents (Class 424/209.1)
-
Patent number: 8114415Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided.Type: GrantFiled: October 20, 2008Date of Patent: February 14, 2012Assignee: Medimmune, LLCInventors: Erich Hoffmann, Hong Jin, Bin Lu, Gregory Duke, George Kemble, Zhongying Chen
-
Publication number: 20120034266Abstract: The present invention provides a new means of restoring the immune system in aging and immunocompromised individuals using an antioxidant nutraceutical. The nutraceutical stimulates the aging immune system through the Nrf2 master gene regulatory pathway. The invention is based in part on the discovery that the Nrf2 has antioxidant and immune restorative activity. The nutraceutical improves function of both the innate and adaptive immune systems.Type: ApplicationFiled: March 3, 2009Publication date: February 9, 2012Inventors: Andre E. Nel, Hyon-Jeen Kim
-
Publication number: 20120027813Abstract: An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus.Type: ApplicationFiled: June 23, 2011Publication date: February 2, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Audino Podda, Nicola Groth, Michele Pellegrini
-
Publication number: 20120020998Abstract: The present invention relates to a method for inducing and amplifying specific effectors, which comprises obtaining pulsed plasmacytoid dendritic cells (pDC) by incubation of a pDC line with at least one antigen, the pulsed pDC being subsequently irradiated and brought into contact with peripheral blood mononuclear cells (PBMC), and cultured or injected into an organism. The pulsed and irradiated pDC and the PBMC share at least one major histocompatibility complex (MHC) allele.Type: ApplicationFiled: May 15, 2009Publication date: January 26, 2012Applicant: ETABLISSEMENT FRANCAIS DU SANGInventors: Joel Plumas, Caroline Aspord, Laurence Chaperot-Dubonnet
-
Publication number: 20120014991Abstract: Adjuvant for mucosal vaccines which modulates the effects of substances, including vaccine antigens in contact with mucosal body surfaces.Type: ApplicationFiled: September 23, 2011Publication date: January 19, 2012Applicant: BIOTEC PHARMACON ASAInventors: Jan RAA, Aud Katherine Herland BERSTAD, Hilde Sunove Waleur BAKKE, Bjorn HANEBERG, Inger LISE HAUGEN, Johan HOLST, Liba JANAKOVA, Gro Ellen KORSVOLD, Fredrik OFTUNG
-
Patent number: 8097459Abstract: In certain aspects, the present invention provides methods for increasing the replication capacity of influenza viruses in hens' eggs and/or cell culture, recombinant and/or reassortant influenza viruses with increased replication capacity, and immunogenic and vaccine compositions comprising such recombinant and/or reassortant influenza viruses. In other aspects, the invention further provides nucleic acids encoding influenza genes associated with increased replication capacity, expression vectors comprising the nucleic acids of the invention, methods for making influenza viruses with increased replication capacity, and kits useful for practice of the methods.Type: GrantFiled: September 1, 2009Date of Patent: January 17, 2012Assignee: Medimmune, LLCInventors: Hong Jin, Bin Lu
-
Publication number: 20120003277Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the invention find use in, among other things, clinical (e.g., therapeutic and preventative medicine (e.g., vaccination)) and research applications.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicants: NANOBIO CORPORATION, THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: James R. Baker, JR., Tarek Hamouda, Susan M. Ciotti
-
Publication number: 20110311586Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: ApplicationFiled: April 19, 2011Publication date: December 22, 2011Applicants: University of Florida Research Foundation, Inc., Intervet International B.V., The Govt. of the U.S.A. as represented by The Secretary of the Dept. of Health & Human Services, Cornell Research Foundation, Inc.Inventors: Patti C. Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, William L. Castleman, Nancy J. Cox
-
Patent number: 8080244Abstract: Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza.Type: GrantFiled: November 20, 2009Date of Patent: December 20, 2011Assignee: Los Alamos National Security, LLCInventor: Andrew M. Bradbury
-
Patent number: 8080255Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.Type: GrantFiled: October 18, 2006Date of Patent: December 20, 2011Assignee: Novavax Inc.Inventors: Gale Smith, Rick Bright, Peter Pushko, Jinyou Zhang, Kutub Mahmood
-
Publication number: 20110293659Abstract: Recombinant yeast cells are produced which are used for vaccination, among other uses for the oral vaccination by feeding.Type: ApplicationFiled: November 13, 2009Publication date: December 1, 2011Inventors: Karin Breunig, Seven-Erik Behrens
-
Publication number: 20110293658Abstract: A method of protecting a mammalian subject against, or treating, a disease, wherein the mammalian subject has elevated numbers and/or activities of MDSC comprising administering to the subject a pharmaceutically acceptable amount of an iNKT agonist, such as alpha galactosylceramide or an analogue thereof, or a TLR agonist, or a combination thereof.Type: ApplicationFiled: November 12, 2009Publication date: December 1, 2011Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Vincenzo Cerundolo, Carmela De Santo
-
Publication number: 20110293660Abstract: The present invention relates to a method for purifying a virus, or a viral antigen thereof, comprising at least the following steps: a) obtaining a fluid comprising the virus, or a viral antigen thereof, and b) purifying the fluid by at least one density gradient ultracentrifugation step, wherein the ratio of the amount of virus, or viral antigen thereof, present in the fluid over the density gradient volume is less than 1, less than 0.8, less than 0.6 and less than 0.4.Type: ApplicationFiled: February 4, 2010Publication date: December 1, 2011Inventors: Bruno Rene Andre, Benoit Paul Suzanne Champluvier
-
Publication number: 20110293723Abstract: Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.Type: ApplicationFiled: May 26, 2011Publication date: December 1, 2011Applicant: Selecta Biosciences, Inc.Inventors: Robert L. Bratzler, Grayson B. Lipford, Lloyd Johnston, Charles Zepp
-
Patent number: 8067013Abstract: A vaccine composition and method which is effective in preventing or ameliorating Avian Influenza Virus infection is set forth herein. The vaccine contains at least two inactivated strains of avian influenza virus, wherein the combined haemoagglutinin (HA) total is at least about 200 HA/dose of the vaccine composition, and wherein each of the strains presents at least about 128 HA/dose, and further wherein one of the strains has the same HA subtype as that of a challenge virus, and wherein at least one of the strains has a different NA subtype than the challenge virus.Type: GrantFiled: October 6, 2005Date of Patent: November 29, 2011Assignee: Wyeth LLCInventors: Juan Plana-Duran, Rut Vila-Quintana, Jordi Tarres-Call, Mahesh Kumar
-
Publication number: 20110287087Abstract: The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of anti-bodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and Chlamydia. The use of adjuvants which selectively give rise to higher levels of IgG2 antibodies will improve the effect of vaccines e.g. against intracellular infections. Furthermore the technology can be used to induce a CD8 response which has been reported to improve the effect of vaccines against e.Type: ApplicationFiled: November 10, 2009Publication date: November 24, 2011Applicant: Statens Serum InstitutInventors: Dennis Christensen, Karen Smith Korsholm, Else Marie Agger, Peter Andersen
-
Publication number: 20110287054Abstract: The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to multivalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from at least two influenza virus strains, at least one strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant.Type: ApplicationFiled: April 28, 2011Publication date: November 24, 2011Inventors: Emmanuel Jules HANON, Jean Stephenne
-
Publication number: 20110280907Abstract: A computer-implemented method and a computer system for identifying a phylogenetic tree from a plurality of biological sequences is provided. Each biological sequence is associated with a sampling date. First, the plurality of biological sequences is aligned and a distance matrix is obtained. Then, a subset of these sequences without any duplicated sequences is selected and a directed graph representation of the subset of biological sequences is generated based the associated sampling dates. Then, a minimum spanning tree is computed from the weighted directed graph representation. Then, in an iterative procedure, the sequences of unsampled evolutionary intermediates are inferred from mutation patterns that reflect the difference in sequence between the nodes in the minimum spanning tree. The new sequences are added with associated time stamps to the sequence set. Then, sets of identical sequences are removed. Then, an optimum branching is recomputed. This step is repeated until no new intermediates are found.Type: ApplicationFiled: November 25, 2009Publication date: November 17, 2011Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.Inventors: Alice Carolyn Mchardy, Lars Steinbruck
-
Patent number: 8057803Abstract: The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.Type: GrantFiled: April 22, 2008Date of Patent: November 15, 2011Assignee: Mount Sinai School of MedicineInventors: Peter Palese, Adolfo Garcia-Sastre, Thomas Muster
-
Publication number: 20110268763Abstract: The polynucleotides of the present invention are complementary to the Initiation Sites of microbes. Invading organisms, sensing the pH and nutrient deprivation of a physiologic environment quickly release these nucleotides triggering rapid growth and mutation—attributes to successfully establishing a nidus of infection. They also stimulate neutrophil functions. Accordingly, the nucleotides, compositions and methods of the present invention may be used to enhance, restore or stimulate an immune response or system of an animal, e.g. to prevent an infection caused by a microorganism, ameliorate an infection caused by a microorganism, or kill an invading microorganism that causes infection or re-establish balance to an immune system. In particular, the polynucleotides, compositions and methods of the present invention may be used to treat or prevent bacterial infections and auto-immune diseases in a mammal in need thereof.Type: ApplicationFiled: February 22, 2011Publication date: November 3, 2011Applicant: IMMUNOM TECHNOLOGIES, INC.Inventor: WILLIAM E. MARSHALL
-
Publication number: 20110268764Abstract: The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or endogenous immune suppressor.Type: ApplicationFiled: May 3, 2011Publication date: November 3, 2011Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AGInventors: Monika Sachet, Michael Bergmann, Thomas Muster, Andrej Egorov
-
Publication number: 20110268762Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to mucosal administration via aerosol spray to avians of immunogenic and vaccine compositions, including those comprising recombinant human adenovirus vectors for delivery of genes encoding avian immunogens or antigens, such as genes encoding avian influenza virus. The invention also provides methods and apparatus for use in such administration.Type: ApplicationFiled: March 25, 2011Publication date: November 3, 2011Inventors: Haroldo Toro, De-Chu C. Tang, Kent R. Van Kampen
-
Patent number: 8048430Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: September 7, 2010Date of Patent: November 1, 2011Assignee: Medimmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Publication number: 20110262482Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.Type: ApplicationFiled: April 21, 2011Publication date: October 27, 2011Applicant: Kineta, Inc.Inventors: Shawn P. Iadonato, Kristin Bedard
-
Patent number: 8043856Abstract: The invention provides adenovirus and retrovirus vectors useful to prepare influenza virus. Also provided is a canine RNA polymerase I promoter and vectors having that promoter.Type: GrantFiled: June 13, 2008Date of Patent: October 25, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Makoto Ozawa
-
Patent number: 8043610Abstract: The objects of the present invention are to provide a freeze-dried composition of an inactivated virus envelop having membrane fusion activity which can be stored at higher temperatures without losing the ability to introduce foreign matters and to provide a method of introducing a foreign matter into a cell with high efficiency. The present invention provides a freeze-dried composition for introducing a foreign matter which comprises an inactivated virus envelope having membrane fusion activity, and at least one stabilizer selected from the group consisting of a protein hydrolysate, leucine, an L-arginine-acid and a polysaccharide, and a method of introducing a foreign matter using the freeze-dried composition containing an inactivated virus envelope.Type: GrantFiled: October 20, 2009Date of Patent: October 25, 2011Assignee: Ishihara Sangyo Kaisha, Ltd.Inventor: Takafumi Ueda
-
Patent number: 8039002Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: August 9, 2007Date of Patent: October 18, 2011Assignee: Medimmune, LLCInventors: Chin-Fen Yang, George Kemble
-
Publication number: 20110250232Abstract: The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus.Type: ApplicationFiled: June 1, 2011Publication date: October 13, 2011Applicant: St Jude Children's Research HospitalInventor: Erich HOFFMANN
-
Publication number: 20110250231Abstract: Disclosed is a method of enhancing the immune response of an animal, including mammals and humans, to prevent or ameliorate immunoinflammatory diseases such as Inflammatory Bowel Disease, increase immune system development, maintain or increase CD4+ and CD8+ T lymphocyte levels, increase immune function, increase immune response against viruses and prevent or ameliorate the Metabolic Syndrome, Type 2 diabetes and obesity by administering orally or parenterally a therapeutically effective amount of punicic acid to the animal.Type: ApplicationFiled: February 23, 2010Publication date: October 13, 2011Inventor: Josep Bassaganya-Riera
-
Publication number: 20110243979Abstract: Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response. Use of skin-active adjuvants is preferred. Although perforation of intact skin is not required, superficial penetration or micropenetration of the skin can act as an enhancer; similarly, hydration may enhance the immune response. This system can induce antigen-specific immune effectors after epicutaneous application of a formulation containing one or more antigen and adjuvant. The formulation may initiate processes such as antigen uptake, processing, and presentation; Langerhans cell activation, migration from the skin to other immune organs, and differentiation to mature dendritic cells; contacting antigen with lymphocytes bearing cognate antigen receptors on the cell surface and their stimulation; and combinations thereof.Type: ApplicationFiled: January 21, 2011Publication date: October 6, 2011Inventors: Gregory M. Glenn, Carl R. Alving
-
Publication number: 20110243987Abstract: The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.Type: ApplicationFiled: June 17, 2011Publication date: October 6, 2011Inventors: Emmanuel Jules Hanon, Jean Stephenne
-
Publication number: 20110236489Abstract: An immunological adjuvant comprises an oil-in-water emulsion, an immunostimulatory oligonucleotide and a polycationic polymer, wherein the oligonucleotide and the polymer ideally associate with each other to form a complex. The adjuvant can be combined with immunogens for preparing vaccines.Type: ApplicationFiled: September 18, 2009Publication date: September 29, 2011Applicant: NOVARTIS AGInventors: Michele Pallaoro, Derek O'Hagan, Rino Rappuoli
-
Publication number: 20110236419Abstract: The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus.Type: ApplicationFiled: February 25, 2011Publication date: September 29, 2011Inventors: Jean-Christophe Audonnet, Jules Minke
-
Publication number: 20110229519Abstract: The present invention relates to a vaccine composition comprising: —at least one prophylactically active agent against influenza, and —at least one adjuvant, said adjuvant being a derivative of a galactosylceramide, for use in the treatment of influenza.Type: ApplicationFiled: October 5, 2009Publication date: September 22, 2011Inventor: Vincent Serra
-
Publication number: 20110229518Abstract: The invention concerns nucleotides vaccines encoding influenza proteins with few or no glycosylation sites. Since these first introductions of pandemic influenzas the viruses have drifted, accumulating mutations at antigenic sites, but also the N-glycosylation pattern has changed during the drifted years, accumulating N-linked glycosylation sequons that help mask the antigenic sites for recognition by the host immune system. These “naked” initial haemagglutinins induce a broad cross reactivity against widely drifted influenza subtypes. The origin of the DNA or RNA can be both pandemic influenza strains, which codes for proteins which have a naturally low content of glycosylation sites and/or DNA or RNA from non-pandemic influenza strains where the nucleotides have been mutated or changed so it encodes for proteins with less or no glycosylation sites. The invention also discloses DNA or RNA encoding the haemagglutinin (HA) from pandemic influenza A, e.g.Type: ApplicationFiled: November 27, 2009Publication date: September 22, 2011Applicant: Statens Serum InstitutInventors: Anders Fomsgaard, Karoline Bragstad
-
Publication number: 20110223197Abstract: Mucosal and systemic administration of compositions comprising alphavirus replicon particles to induce immune responses in a subject is described.Type: ApplicationFiled: October 17, 2006Publication date: September 15, 2011Applicant: NOVARTIS VACCINES AND DIAGNOSTICS INC.Inventor: Michael Vajdy
-
Publication number: 20110223199Abstract: The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity.Type: ApplicationFiled: November 25, 2009Publication date: September 15, 2011Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AGInventors: Julia Romanova, Andrej Egorov, Brigitte Krenn, Markus Wolschek, Sabine Nakowitsch
-
Publication number: 20110223230Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.Type: ApplicationFiled: May 19, 2011Publication date: September 15, 2011Applicant: ASCENDIS PHARMA A/SInventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
-
Publication number: 20110223195Abstract: The invention relates to vaccine compositions comprising chitosan and a vaccine which are administered to avian species via the ocular route, and methods or programs of vaccination including use of chitosan in order to increase or enhance cell-mediated immunity in avian species and persistence of the vaccine avian tissues.Type: ApplicationFiled: September 4, 2009Publication date: September 15, 2011Applicant: CEVA SANTE ANIMALE SAInventors: Yannick Gardin, Vilmos Palya, Sylvain Comte
-
Publication number: 20110223198Abstract: Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsRNA together with an anti-influenza vaccine.Type: ApplicationFiled: April 19, 2011Publication date: September 15, 2011Applicant: HEMISPHERx BIOPHARMAInventors: William A. Carter, David Strayer
-
Patent number: 8017154Abstract: Use of a polyamino acid as an adjuvant; an application of a polyamino acid as an adjuvant in the production of a vaccine; a vaccine comprising a polyamino acid as an adjuvant; a biodegradable nanoparticle having a virus antigen immobilized thereon; and a vaccine comprising the biodegradable nanoparticle.Type: GrantFiled: July 27, 2009Date of Patent: September 13, 2011Assignees: Mitsuru Akashi, Masanori BabaInventors: Mitsuru Akashi, Masanori Baba
-
Publication number: 20110217244Abstract: The use of oxidatively transformed carotenoid or a component thereof to enhance the immune response in a subject for the treatment of infection or to enhance the immune response to an antigen in a subject being immunized. Also disclosed are pharmaceutical compositions and kits containing the oxidatively transformed carotenoid.Type: ApplicationFiled: October 23, 2008Publication date: September 8, 2011Applicant: National Research Council of CanadaInventors: James Johnston, Bozena Korczak, Graham Burton
-
Patent number: 8012490Abstract: The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. Tumor-bearing patients can be immunized with the recombinant influenza viruses alone, or in combination with another treatment, to induce an immune response that leads to tumor reduction. The recombinant viruses can also be used to vaccinate high risk tumor-free patients to prevent tumor formation in vivo.Type: GrantFiled: September 22, 2009Date of Patent: September 6, 2011Assignees: Mount Sinai School of Medicine, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Peter Palese, Adolfo Garcia-Sastre, Nicholas P. Restifo
-
Publication number: 20110212123Abstract: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound.Type: ApplicationFiled: February 22, 2011Publication date: September 1, 2011Inventors: Haixiang Lin, Lie Tao Victor Li
-
Publication number: 20110212129Abstract: The invention relates to a method for producing flu virus according to which: a) immunizing a hen by administering a flu vaccine to the hen, b) triggering embryogenesis in one or more eggs of the immunized hen, c) infecting the one or more embryonated eggs by inoculating a flu virus into the allantoic cavity of the eggs, d) incubating the one or more infected embryonated eggs under temperature and humidity conditions that allow replication of the virus, and e) harvesting the allantoic fluid of the one or more incubated eggs containing the virus.Type: ApplicationFiled: December 7, 2010Publication date: September 1, 2011Applicants: SANOFI PASTEUR S.A., MERIAL LIMITEDInventors: Catherine Gerdil, Catherine Moste, Isabelle Legastelois, Michel Marie Joseph Bublot, François-Xavier Le Gros
-
Publication number: 20110195091Abstract: When ELISA antibody titer dropped in chickens intramuscularly inoculated with an oil vaccine, recombinant HA and NP antigens prepared using gene recombinant technology were orally administered in combination with synthetic oligo CpG as a mucosal adjuvant to the chickens. Even when the immune response induced with the oil vaccine was impaired, the antibody titer was re-induced by orally administering the recombinant HA and NP antigens, and synthetic CpG-ODN in combination.Type: ApplicationFiled: August 13, 2009Publication date: August 11, 2011Applicant: THE KITASATO INSTITUTEInventors: Yukihiro Miyoshi, Akira Ito, Kentaro Susa, Naomi Himeno, Toru Gotanda
-
Patent number: 7993652Abstract: The present invention relates to an influenza antigen, comprising a fusion product of at least the extracellular part of a conserved influenza membrane protein or a functional fragment thereof and a presenting carrier, which may be a presenting (poly)peptide or a non-peptidic structure, such as glycans, peptide mimetics, synthetic polymers. The invention further relates to a vaccine against influenza, comprising at least an antigen of the invention, optionally in the presence of one or more excipients. The invention also relates to use of the antigen, a method for preparing the antigen and acceptor cells expressing the antigen.Type: GrantFiled: June 7, 2010Date of Patent: August 9, 2011Assignee: FVlaams Interuniversitair Instituut Voors BiotechnologieInventors: Sabine Neirynck, Willy Min Jou, Walter Fiers
-
Publication number: 20110189231Abstract: Adjuvants comprising OmpC porin, OmpF porin, or a combination thereof, are provided. The adjuvants can be administered to a subject in combination with antigenic material in order to potentiate the immunogenic effect of the antigenic material. Also provided are products comprising antigenic material in combination with OmpC and/or OmpF, including products comprising a pre-formulated vaccine in combination with OmpC and/or OmpF. Further provided is the use of OmpC and/or OmpF to improve the effect of a pre-formulated vaccine.Type: ApplicationFiled: June 17, 2009Publication date: August 4, 2011Inventors: Denis Leclerc, Constantino Roberto Lopez-Macias, III
-
Publication number: 20110182857Abstract: Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.Type: ApplicationFiled: April 1, 2011Publication date: July 28, 2011Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Peter James WATTS, Lisbeth ILLUM
-
Publication number: 20110182829Abstract: The present invention is directed to a method of increasing the time period between outbreaks of genital herpes comprising providing an imidazoquinolinamine formulation, disposing an amount of the imidazoquinolinamine formulation into a first nare of an individual infected with Herpes Simplex Virus type 2, covering at least a portion of the internal surface of the individual's first nare with a portion of the amount of the imidazoquinolinamine in the nare, massaging the portion of the amount of the imidazoquinolinamine into the internal surface of the first nare, disposing the amount of the imidazoquinolinamine formulation into a second nare of the individual, covering at least a portion of the internal surface of the second nare with a portion of the amount of the imidazoquinolinamine in said nare and massaging the portion of the amount of the imidazoquinolinamine into the internal surface of said nare.Type: ApplicationFiled: February 21, 2011Publication date: July 28, 2011Inventor: Eugene Mandrea